Please login to the form below

Not currently logged in
Email:
Password:

GCI Health’s global footprint takes another step

The WPP-owned healthcare communications agency has opened its first London office
Rikki Jones

WPP-owned healthcare communications agency GCI Health has advanced its global ambitions with the launch of a London office.

The London business will focus on further building GCI Health's client base across four primary service areas: life sciences, consumer health, market access communications and strategic consulting.

Launched to cope with a growing European client base, the new business will be headed up by Rikki Jones (pictured), previously director at fellow WPP agency Cohn & Wolfe, and associate director Louise Veale, who has also moved from within the WPP network.

“We couldn't be more thrilled with the market's response to date and are looking forward to continued London-based success, in partnership with the rest of GCI Health's global management team,” said Jones.

Formally opened on October 15, 2013, the business is already up and running, describing itself as 'a trusted partner to six client companies at the global, European and UK levels in the areas of oncology, virology, auto-immune disease, diabetes and respiratory diseases'.

WPP's only speciality healthcare communications agency, GCI Health employs more than 140 people, across the US, Canada and Europe. To date, the company has worked with European clients from its US headquarters, but says that the time is now right to establish a European base.

“We had been successfully servicing global business, but as the international healthcare market continues to evolve, the time was right to find European based leaders with the passion and experience to take our business expansion to the next level,” said GCI Health chief executive Wendy Lund.

17th October 2013

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...